author-photo

Tanja Badovinac-Crnjevic

Hoffmann-La Roche

26

Papers

1031

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (15)
Abstract PS7-23: Neoadjuvant and adjuvant therapy (NAT/AT) treatment patterns and clinical characteristics in a real-world cohort of US patients with HR+/HER2− early breast cancer (eBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT-09-06: Phase II neoadjuvant study of GDC-9545 + palbociclib (palbo) vs anastrozole (A) + palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2- eBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD4-07: Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27

2018 Journal of the National Cancer Institute
Show All
- Source
- Cite
- Save
Citations (8)
Changes in patient (pt), tumor, and treatment characteristics over time in 1st line (1L) trastuzumab (H) plus taxane (T; paclitaxel/docetaxel) arms in HER2-positive metastatic breast cancer (MBC) trials.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer

2017 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (22)
Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (MBC) previously treated with pertuzumab (P).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (207)